Product Description
Mechanisms of Action: CYP51 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: United States
Approved Indications: Candidiasis | Candidiasis, Vulvovaginal
Known Adverse Events: Headache
Company: Viamet
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Candidiasis, Vulvovaginal
Phase 2: Candidiasis, Vulvovaginal|Onychomycosis|Tinea Pedis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ultraVIOLET | P3 |
Completed |
Candidiasis, Vulvovaginal |
2020-12-02 |
|
| VIOLET | P3 |
Completed |
Candidiasis, Vulvovaginal |
2020-10-19 |
|
| 2018-001269-18 | P3 |
Completed |
Candidiasis, Vulvovaginal |
2020-10-19 |
|
| VIOLET | P3 |
Completed |
Candidiasis, Vulvovaginal |
2020-10-13 |